A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Pfizer
Eli Lilly and Company
BioNTech SE
Astellas Pharma Inc
Boehringer Ingelheim
Janssen Research & Development, LLC
Janssen Research & Development, LLC
AstraZeneca
RayzeBio, Inc.
Amgen
Genmab
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
AstraZeneca
Zai Lab (Hong Kong), Ltd.
Debiopharm International SA
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Merck Sharp & Dohme LLC
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Inhibrx Biosciences, Inc
Pfizer
RemeGen Co., Ltd.
Amgen
BeOne Medicines
Merck Sharp & Dohme LLC
AstraZeneca
HC Biopharma Inc.
Eli Lilly and Company
Hoffmann-La Roche
GlaxoSmithKline
Boehringer Ingelheim
Debiopharm International SA
Hoffmann-La Roche
Blueprint Medicines Corporation
Merck Sharp & Dohme LLC
Tesaro, Inc.
Amgen
AbbVie
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
BeiGene
Eli Lilly and Company
AbbVie
Toray Industries, Inc
HRYZ Biotech Co.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Jemincare
Merck Sharp & Dohme LLC
EMD Serono